NCT00967811View on ClinicalTrials.gov

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Formulation E1 of L-PPDS

Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

DRUG

Formulation E2 of L-PPDS

Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

Trial Locations (1)

94025

Menlo Park

Sponsors
All Listed Sponsors
lead

Mati Therapeutics Inc.

INDUSTRY

NCT00967811 - A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG | Biotech Hunter | Biotech Hunter